Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Acquires 6,758 Shares

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) Director Wladimir Hogenhuis bought 6,758 shares of the company's stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $2.92 per share, for a total transaction of $19,733.36. Following the acquisition, the director now directly owns 84,025 shares of the company's stock, valued at approximately $245,353. This represents a 8.75 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Wladimir Hogenhuis also recently made the following trade(s):

• On Tuesday, February 18th, Wladimir Hogenhuis purchased 10,000 shares of Rezolute stock. The stock was bought at an average cost of $4.70 per share, with a total value of $47,000.00.

Rezolute Stock Down 7.5 %

NASDAQ:RZLT traded down $0.21 during mid-day trading on Friday, hitting $2.54. 332,083 shares of the stock traded hands, compared to its average volume of 491,854. The business's 50-day moving average price is $4.10 and its 200 day moving average price is $4.69. The company has a market cap of $153.46 million, a PE ratio of -2.07 and a beta of 0.97. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RZLT shares. JMP Securities upped their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Rezolute in a research report on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Finally, Guggenheim restated a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Rezolute currently has a consensus rating of "Buy" and a consensus target price of $24.38.

Institutional Trading of Rezolute

Several institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. purchased a new position in Rezolute in the third quarter worth $42,000. Alpine Global Management LLC purchased a new position in shares of Rezolute in the 4th quarter worth about $54,000. MML Investors Services LLC purchased a new position in shares of Rezolute during the 3rd quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute in the 3rd quarter worth approximately $65,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after buying an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.